
GoodRx Review
Tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.9/10
Best for: oral orforglipron alongside the injectables
GoodRx's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. It publishes self-pay discount pricing on brand-name GLP-1 medications, with Foundayo (orforglipron) starting at $149/month and the Zepbound KwikPen (tirzepatide) starting at $299/month, redeemable at 70,000+ pharmacies nationwide. It also operates GoodRx Care, a telehealth arm that prescribes GLP-1s with online visits starting at $39.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to GoodRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
GoodRx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Zepbound
- Starting price
- $149/mo
- Pricing model
- Scales with dose — higher doses cost more
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How GoodRx scores
Six columns, each one computed from something GoodRx has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
5.0/10$149/month is exactly the register median for brand orforglipron.
Effectiveness25%
10.0/10Dispenses orforglipron and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
5.0/10Where this seller first shows a price is not recorded yet, so the signup is unscored and sits at the midpoint.
Trust & Safety15%
6.0/10does not name a dispensing pharmacy; withholds price until after the intake; publishes its state list. Our verification confidence is high.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on GoodRx
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
GLP-1 medications GoodRx offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off GoodRx's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide at $299 a month, 76% below the $1249 median for the same drug and form across this register
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What GoodRx sells is a coupon, and that changes the whole comparison
Fill out a form, get a script from a clinician, wait for a pharmacy to ship: that is the shape of nearly every provider in this register. GoodRx does not work that way. It is the country's biggest prescription-savings platform (NASDAQ: GDRX), and what it actually sells is a coupon. Arrive at a pharmacy counter with a valid GLP-1 prescription, show the GoodRx card or code, and the self-pay rate you are charged is discounted off the sticker price. Everything about who this suits, and who it does not, follows from that one difference.
On the numbers, it holds up well. At its lowest dose, brand-name Foundayo (orforglipron) starts at $149 a month. A few hundred dollars buys the Zepbound KwikPen (tirzepatide). Both figures land well below what these drugs usually cost a patient with no coverage. Set against a category median of about $169 across the providers we track, brand pricing through GoodRx competes even with compounded programs.
Where the discount comes from
Lilly supplies this discount through GoodRx directly. It is not a third party negotiating a rate down, which is why the numbers stay this low on FDA-approved brand product instead of on a compounded copy. What you see is a cash price, paid at the counter. Insurance is not involved at any point, so nothing here reduces your deductible. Nor is there a membership to buy. The card is free and there is no subscription behind it.
One caveat deserves stating plainly. That $149 Foundayo figure applies to the lowest dose only. GoodRx publishes its own Foundayo table, and the price climbs with the tablet strength, reaching a few hundred dollars a month at the higher ones. Dose-scaling like that is normal for the drug class. It does mean that if you titrate up, the number worth budgeting against is the higher tier and not the headline.
What is available here, and what is not
- Foundayo (orforglipron) — the brand-name oral GLP-1 from Lilly, starting at $149 for the lowest dose
- Zepbound KwikPen (tirzepatide) — the brand-name injectable, discounted to a self-pay rate far below the cash list Lilly normally charges
- Brand only — no compounded semaglutide or compounded tirzepatide is available through GoodRx
- 70,000+ pharmacies — of every GLP-1 channel we cover, this card has the largest retail network behind it
The 70,000-pharmacy reach is the real differentiator
A telehealth GLP-1 provider usually ships from one or two partner pharmacies, on its own schedule. The card model inverts that. More than 70,000 US pharmacies honor it, so the counter you already use works: the chain down the road, the one inside your grocery store, whichever is convenient. No shipping window to wait out, and no bottleneck at a single pharmacy. For a patient who wants to walk in, collect a real FDA-approved brand product that day, and skip mail order entirely, nothing else in our coverage is close. The same mechanism explains the 50-state availability. Retail pharmacy infrastructure already exists everywhere, so there is no state-by-state telehealth footprint to build.
A prescriber is still required, though GoodRx can be one
No discount card writes prescriptions. Until a clinician has put orforglipron or tirzepatide on a script, the coupon does nothing for you. If your own doctor has written one already, GoodRx becomes a pure savings tool and nothing else needs arranging. Otherwise the company's telehealth arm, GoodRx Care, runs online visits for a per-visit fee in the low-to-mid two figures, less again for Gold members, and it can issue GLP-1 prescriptions itself. Few options in this market cover both halves. Treat them as two steps rather than one, and remember that the visit fee sits on top of what the medication costs.
Who this is for, and who should look elsewhere
GoodRx fits if what you want is FDA-approved brand medication bought at a self-pay price, picking up locally matters to you, and you either hold a prescription already or are willing to get one through GoodRx Care. It is worth a look purely as a price check, too. Patients who are with another provider sometimes still come out ahead filling brand product on the GoodRx card.
Look elsewhere if compounded semaglutide or tirzepatide is specifically what you want, because GoodRx carries neither, and compounded programs are frequently cheaper month to month. Look elsewhere too if the plan was to have this count toward your insurance benefits; it is self-pay only and your deductible will not move. Prices here can also change as Lilly's coupon program develops, so check the current rate before committing to anything.
Trust and safety
No FDA warnings sit on file against GoodRx, and the reason the safety picture stays clean is structural rather than lucky. Nothing is compounded here, and no dispensing pharmacy of its own is involved in these drugs. What reaches you is the genuine FDA-approved brand product, Lilly's Foundayo and Zepbound, handed over by the licensed retail pharmacies you already deal with. Because the manufacturer stands behind the discount, there is no opaque third-party markup in the middle either, and GLP-1 pricing rarely gets more transparent than that. Check the live rate yourself, though, because coupon prices update often. Our scoring methodology sets out how these factors are weighed.
Bottom line
One job gets done here better than anywhere else: putting genuine brand-name GLP-1 medication in your hands at a self-pay price that is fair, usable at almost any counter, without a membership and without waiting on the mail. For brand Foundayo and the Zepbound KwikPen, this is the strongest channel in our coverage provided you hold a prescription, and GoodRx Care can supply that prescription too. The limits are real and worth stating: nothing compounded, nothing applied to insurance, a price that scales past the $149 headline as your dose rises, and rates that move with Lilly's program. Weigh brand-name access and convenience against the lowest compounded price, and if the first pair wins, this is hard to beat.
For a like-for-like, HealthRX ($133/month) and Found ($149/month) are the two we would put beside GoodRx.
The Bottom Line
GoodRx's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay GoodRx
Starting at $149/month. Check today's price, then book the free consultation.
Where GoodRx is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this GoodRx review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 7.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See GoodRx's current pricing
Plans start at $149/month. The free consultation is where you learn whether you qualify, and what it costs today.